Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, phase 2 study to assess the feasibility of using
cabozantinib in recurrent/metastatic Merkel Cell Carcinoma patients that progressed after
platinum-based therapy.